Adult atopic dermatitis (AD), specifically late-onset phe-
notypes, is characterized by a notable degree of clinical
heterogeneity in terms of morphologic and topographic
characteristics. Alongside the classic flexural AD presen-
tation, adult patients can manifest other less common pheno-
types, including prurigo nodularis-like, nummular eczema
and generalized/erythrodermic, that may exhibit variations
in immune and skin barrier proteins with potential influence
on topical and systemic therapies' efficacy.
Upadacitinib,
a JAK 1 inhibitor indicated for treatment of patients aged
≥12years with moderate-to-severe AD, has shown good
short- and long-term efficacy and a favourable safety profile
both in randomized clinical trials and real-world studies.
However, the effectiveness of upadacitinib in distinct AD
clinical phenotypes has not been investigated.
Product ID:
146292
Handle IRIS:
11562/1165009
Last Modified:
June 18, 2025
Bibliographic citation:
Gori, Niccolò; Quaglino, Pietro; Chiricozzi, Andrea; Valerio Marzano, Angelo; Argenziano, Giuseppe; Girolomoni, Giampiero; Bianchi, Luca; Concetta Fargnoli, Maria; Ortoncelli, Michela; Di Nardo, Lucia; Mariel Ferrucci, Silvia; Caccavale, Stefano; Maurelli, Martina; Galluzzo, Marco; Esposito, Maria; Peris, Ketty,
Successful response of upadacitinib in different clinical phenotypes
of atopic dermatitis«Journal of the European Academy of Dermatology and Venereology»
, 2025
, pp. 547-549